Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer

Human Pathology

Volumn 40, Issue 2, 2009, Pages 156-165

  Sullivan, C A W ^a   Ghosh, S ^a   Ocal, I T ^b   Camp, R L ^b   Rimm, David L ^b   Chung, G G ^a  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Automated image analysis; Breast cancer; Microvessel area

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; CYTOKERATIN; ESTROGEN RECEPTOR;

ADULT; ANGIOGENESIS; ARTICLE; AUTOMATED QUANTITATIVE ANALYSIS; BREAST CANCER; DIAGNOSTIC PROCEDURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; PROGNOSIS; REPRODUCIBILITY; SURVIVAL; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ANTIGENS, CD31; AUTOMATION; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS;

EID: 58149121274     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.07.005     Document Type: Article

References (33)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
2. North S., Moenner M., and Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 218 (2005) 1-14
3. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
4. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
5. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
6. Patan S., Munn L.L., and Jain R.K. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 51 (1996) 260-272
7. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
8. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
9. Mlynek M.L., van Beunigen D., Leder L.D., and Streffer C. Measurement of the grade of vascularisation in histological tumour tissue sections. Br J Cancer 52 (1985) 945-948
10. Uzzan B., Nicolas P., Cucherat M., and Perret G.Y. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64 (2004) 2941-2955
11. Vincent-Salomon A., Carton M., Zafrani B., et al. Long term outcome of small size invasive breast carcinomas independent from angiogenesis in a series of 685 cases. Cancer 92 (2001) 249-256
12. Adams J., Carder P.J., Downey S., et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 60 (2000) 2898-2905
13. Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., and Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97 (2001) 3658-3661
14. Shaked Y., Bertolini F., Man S., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 (2005) 101-111
15. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K.H., and Augustin H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60 (2000) 1388-1393
16. Camp R.L., Chung G.G., and Rimm D.L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8 (2002) 1323-1327
17. Chung G.G., Yoon H.H., Zerkowski M.P., et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 106 (2006) 1677-1684
18. Psyrri A., Yu Z., Weinberger P.M., et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 11 (2005) 5856-5862
19. Zerkowski M.P., Camp R.L., Burtness B.A., Rimm D.L., and Chung G.G. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest 25 (2007) 19-26
20. DiVito K.A., Charette L.A., Rimm D.L., and Camp R.L. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 84 (2004) 1071-1078
21. Dolled-Filhart M., McCabe A., Giltnane J., Cregger M., Camp R.L., and Rimm D.L. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res 66 (2006) 5487-5494
22. Altman D.G., Lausen B., Sauerbrei W., and Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86 (1994) 829-835
23. Camp R.L., Dolled-Filhart M., and Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10 (2004) 7252-7259
24. Pick E., Kluger Y., Giltnane J.M., et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 67 (2007) 2932-2937
25. Hansen S., Grabau D.A., Sorensen F.B., Bak M., Vach W., and Rose C. Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer 82 (2000) 339-347
26. Dales J.P., Garcia S., Carpentier S., et al. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 35 (2004) 176-183
27. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
28. McCabe A., Dolled-Filhart M., Camp R.L., and Rimm D.L. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97 (2005) 1808-1815
29. Chantrain C.F., DeClerck Y.A., Groshen S., and McNamara G. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J Histochem Cytochem 51 (2003) 151-158
30. Charpin C., Dales J.P., Garcia S., et al. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res 10 (2004) 5815-5819
31. Fox S.B., Leek R.D., Weekes M.P., Whitehouse R.M., Gatter K.C., and Harris A.L. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol 177 (1995) 275-283
32. Schneider B.P., and Sledge Jr. G.W. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 4 (2007) 181-189
33. Jain R.K., Duda D.G., Clark J.W., and Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40